• Harrow recently presented three studies at the ASRS 2026 Annual Meeting highlighting interim clinical and real-world data for IHEEZO and BYOOVIZ in retinal care.
• The early IHEEZO data suggesting improved post-injection comfort without added antisepsis risk could meaningfully influence how ophthalmologists think about intravitreal procedures.
• We’ll now explore how encouraging interim IHEEZO pain and safety findings may influence Harrow’s investment narrative built around retina expansion.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Harrow Investment Narrative Recap

To own Harrow, you need to believe its concentrated ophthalmic portfolio can justify current growth expectations while management executes on retina-focused expansion. The ASRS data around IHEEZO and BYOOVIZ supports that retina narrative, but the most important near term catalyst still looks like delivering on ambitious 2026 revenue guidance, with a key risk that new product launches, including in retina, ramp more slowly than expected.

Among recent developments, Harrow’s reaffirmation of full year 2026 revenue guidance of US$350 million to US$365 million feels most relevant here. The encouraging interim IHEEZO data and large real world safety analysis now sit against that backdrop, potentially affecting how investors judge the credibility of those guidance targets and the balance between upside from retina expansion and execution risk across the broader portfolio.

Yet behind the promising retina data, investors should be aware of how much depends on sustained uptake of new ophthalmic launches and...

Harrow's narrative projects $784.8 million revenue and $246.0 million earnings by 2029. This requires 42.9% yearly revenue growth and a $261.0 million earnings increase from -$15.0 million today.

Uncover how Harrow's forecasts yield a $68.38 fair value, a 77% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already projecting Harrow to reach about US$706.7 million revenue and US$139.6 million earnings by 2029, yet they still framed heavy reliance on ophthalmic launches and execution risk across biosimilars and retina products as a much more cautious story than the consensus view, and the new IHEEZO and BYOOVIZ data could eventually shift how you weigh that pessimism.

Explore 3 other fair value estimates on Harrow - why the stock might be worth just $59.00!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Harrow research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Harrow research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harrow's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.